Literature DB >> 29934424

Validation and utilization of amended diagnostic criteria in Creutzfeldt-Jakob disease surveillance.

Peter Hermann1, Mareike Laux1, Markus Glatzel1, Jakob Matschke1, Tobias Knipper1, Stefan Goebel1, Johannes Treig1, Walter Schulz-Schaeffer1, Maria Cramm1, Matthias Schmitz1, Inga Zerr2.   

Abstract

OBJECTIVE: To validate an amended protocol for clinical diagnosis of sporadic Creutzfeldt-Jakob disease (sCJD) including real-time quaking-induced conversion (RT-QuIC) and to observe its use in CJD surveillance.
METHODS: In the framework of a prospective epidemiologic study, all neuropathologically confirmed cases with sCJD who received CSF RT-QuIC analysis during diagnostic workup (n = 65) and a control group of individuals without CJD (n = 118) were selected to investigate the accuracy of an amended diagnostic protocol. The patients had been referred to the German National Reference Center for Transmissible Spongiform Encephalopathies. The influence of the amended protocol on incidence figures was evaluated in the context of 3 years of surveillance activity (screened cases using 14-3-3 test n = 18,789, highly suspicious cases of CJD n = 704). Annual incidences were calculated with current criteria and the amended protocol.
RESULTS: The amended protocol showed a sensitivity of 97% and a specificity of 99%. When it was applied to all suspected cases who were referred to the reference center, the assessed incidence of CJD increased from 1.7 to 2.2 per million in 2016.
CONCLUSION: CJD surveillance remains challenging because information from external health care institutions can be limited. RT-QuIC shows excellent diagnostic accuracy when applied in the clinical setting to symptomatic patients. Data for RT-QuIC alone when applied as a general screening test are not available yet. We propose an amended research protocol that improves early and accurate clinical diagnosis of sCJD during surveillance activities. The use of this protocol will probably lead to a significant increase of the incidence rate. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for patients with suspected sCJD, criteria for clinical diagnosis plus the CSF RT-QuIC accurately identifies patients with sCJD (sensitivity 97%, specificity 99%).
© 2018 American Academy of Neurology.

Entities:  

Mesh:

Year:  2018        PMID: 29934424     DOI: 10.1212/WNL.0000000000005860

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  30 in total

1.  Domain-specific Quantification of Prion Protein in Cerebrospinal Fluid by Targeted Mass Spectrometry.

Authors:  Eric Vallabh Minikel; Eric Kuhn; Alexandra R Cocco; Sonia M Vallabh; Christina R Hartigan; Andrew G Reidenbach; Jiri G Safar; Gregory J Raymond; Michael D McCarthy; Rhonda O'Keefe; Franc Llorens; Inga Zerr; Sabina Capellari; Piero Parchi; Stuart L Schreiber; Steven A Carr
Journal:  Mol Cell Proteomics       Date:  2019-09-26       Impact factor: 5.911

2.  [Sporadic Creutzfeldt-Jakob disease imitates posterior reversible encephalopathy syndrome].

Authors:  Schulamith Krüger; Jörg Larsen; Jens Schaumberg
Journal:  Nervenarzt       Date:  2019-06       Impact factor: 1.214

3.  Structural signature of sporadic Creutzfeldt-Jakob disease.

Authors:  J Navid; G S Day; J Strain; R J Perrin; R C Bucelli; A Dincer; J K Wisch; D Soleimani-Meigooni; J C Morris; T L S Benzinger; B M Ances
Journal:  Eur J Neurol       Date:  2019-03-25       Impact factor: 6.089

Review 4.  Rapidly Progressive Dementia.

Authors:  Gregory S Day
Journal:  Continuum (Minneap Minn)       Date:  2022-06-01

5.  Establishing a committee for antemortem reviews of suspect Creutzfeldt-Jakob disease cases in Ireland.

Authors:  Conor Fearon; Rachel Howley; Seamus Looby; Amber Byrne; Josephine Heffernan; Ciara Heeney; Alan Beausang; Jane Cryan; Michael Farrell; Sean O'Dowd; Francesca Brett
Journal:  Ir J Med Sci       Date:  2022-07-15       Impact factor: 2.089

6.  Creutzfeldt-Jakob disease after COVID-19: infection-induced prion protein misfolding? A case report.

Authors:  Andrea Bernardini; Gian Luigi Gigli; Francesco Janes; Gaia Pellitteri; Chiara Ciardi; Martina Fabris; Mariarosaria Valente
Journal:  Prion       Date:  2022-12       Impact factor: 2.547

Review 7.  Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease.

Authors:  Peter Hermann; Brian Appleby; Jean-Philippe Brandel; Byron Caughey; Steven Collins; Michael D Geschwind; Alison Green; Stephane Haïk; Gabor G Kovacs; Anna Ladogana; Franc Llorens; Simon Mead; Noriyuki Nishida; Suvankar Pal; Piero Parchi; Maurizio Pocchiari; Katsuya Satoh; Gianluigi Zanusso; Inga Zerr
Journal:  Lancet Neurol       Date:  2021-03       Impact factor: 44.182

Review 8.  The importance of ongoing international surveillance for Creutzfeldt-Jakob disease.

Authors:  Neil Watson; Jean-Philippe Brandel; Alison Green; Peter Hermann; Anna Ladogana; Terri Lindsay; Janet Mackenzie; Maurizio Pocchiari; Colin Smith; Inga Zerr; Suvankar Pal
Journal:  Nat Rev Neurol       Date:  2021-05-10       Impact factor: 42.937

Review 9.  State-of-the-Art Methods and Emerging Fluid Biomarkers in the Diagnostics of Dementia-A Short Review and Diagnostic Algorithm.

Authors:  Eino Solje; Alberto Benussi; Emanuele Buratti; Anne M Remes; Annakaisa Haapasalo; Barbara Borroni
Journal:  Diagnostics (Basel)       Date:  2021-04-27

10.  Creutzfeldt-Jakob disease in pregnancy: the use of modified RT-QuIC to determine infectivity in placental tissues.

Authors:  Collin C Luk; Candace K Mathiason; Christina D Orrù; Gerard H Jansen; Allison Thiele; Byron Caughey; Valerie L Sim
Journal:  Prion       Date:  2021-12       Impact factor: 3.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.